| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 780.76M | 647.04M | 508.69M | 324.52M | 222.56M | 110.64M |
| Gross Profit | 570.97M | 468.32M | 358.23M | 218.05M | 153.18M | 77.83M |
| EBITDA | 140.50M | 125.43M | 82.92M | 32.07M | 23.52M | 20.92M |
| Net Income | 110.16M | 101.49M | 58.53M | 21.73M | 13.92M | 11.71M |
Balance Sheet | ||||||
| Total Assets | 1.11B | 438.88M | 404.91M | 216.41M | 142.97M | 81.75M |
| Cash, Cash Equivalents and Short-Term Investments | 639.71M | 100.22M | 115.65M | 40.95M | 28.83M | 39.77M |
| Total Debt | 23.84M | 22.71M | 12.51M | 15.88M | 5.35M | 5.49M |
| Total Liabilities | 728.45M | 156.58M | 121.80M | 117.70M | 74.32M | 29.40M |
| Stockholders Equity | 380.68M | 282.30M | 283.11M | 98.70M | 68.65M | 52.35M |
Cash Flow | ||||||
| Free Cash Flow | 102.09M | 129.76M | 81.84M | 31.25M | 3.12M | 19.75M |
| Operating Cash Flow | 108.70M | 137.76M | 87.45M | 39.03M | 9.87M | 23.02M |
| Investing Cash Flow | -46.45M | 1.35M | -139.99M | -25.78M | -18.78M | 6.67M |
| Financing Cash Flow | 443.82M | -127.30M | 48.81M | -246.00K | -318.00K | 161.00K |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
73 Outperform | $1.94B | 19.76 | 29.74% | ― | 25.80% | 10.73% | |
73 Outperform | $4.82B | 21.46 | ― | ― | 14.20% | 204.86% | |
69 Neutral | $1.89B | 28.47 | 9.79% | ― | 10.58% | -45.52% | |
66 Neutral | $4.20B | 56.75 | 20.46% | ― | 18.37% | ― | |
65 Neutral | $2.81B | -1,434.07 | 0.58% | ― | 24.71% | 99.52% | |
61 Neutral | $37.18B | 12.37 | -10.20% | 1.83% | 8.50% | -7.62% | |
61 Neutral | $2.69B | -81.14 | -8.95% | ― | 11.05% | 45.23% |
On January 12, 2026, ODDITY Tech Ltd. disclosed that it has amended its existing agreements with a syndicate of banks to secure expanded credit facilities totaling $350 million, effective January 15, 2026, replacing its previous $200 million lines of credit. The new undrawn facilities, available for three years through January 14, 2029, are designed to enhance the company’s financial flexibility to support growth initiatives, acquisitions, share buybacks and other general corporate purposes, with borrowings priced at SOFR plus 2.7% for term loans maturing January 14, 2031 and a 0.3% commitment fee on unused amounts; the facilities are backed by a negative pledge and subsidiary guarantees and include standard covenants, notably a net debt-to-EBITDA cap of 4x, underscoring a balanced approach to leveraging for expansion while maintaining financial discipline for stakeholders.
The most recent analyst rating on (ODD) stock is a Buy with a $50.00 price target. To see the full list of analyst forecasts on ODDITY Tech Ltd. Class A stock, see the ODD Stock Forecast page.
On January 7, 2026, ODDITY Tech Ltd. reported that Dr. Ido Bachelet, formerly Chief Science Officer of ODDITY LABS, is no longer employed by the company, with his responsibilities redistributed among the existing ODDITY LABS leadership team. The company emphasized that his departure did not stem from any disagreement over operations, policies, or practices and stated that the organizational change is not expected to affect its financial outlook or disrupt ODDITY LABS’ operations, including current product development and commercialization timelines, signaling continuity and stability for stakeholders despite the leadership change.
The most recent analyst rating on (ODD) stock is a Buy with a $80.00 price target. To see the full list of analyst forecasts on ODDITY Tech Ltd. Class A stock, see the ODD Stock Forecast page.
On November 19, 2025, ODDITY Tech Ltd. announced its financial results for the third quarter ending September 30, 2025, reporting a record net revenue of $148 million, a 24% increase year-over-year. The company exceeded its financial guidance across all metrics and launched METHODIQ, a new brand targeting the medical care system. With a strong cash position and ongoing investments in technology and brand development, ODDITY is well-positioned for future growth, leading to an increased financial outlook for the full year.
The most recent analyst rating on (ODD) stock is a Buy with a $44.00 price target. To see the full list of analyst forecasts on ODDITY Tech Ltd. Class A stock, see the ODD Stock Forecast page.
On November 18, 2025, ODDITY Tech Ltd. announced the launch of METHODIQ, a telehealth platform designed to transform medical care through AI-driven, customized treatments. METHODIQ initially targets dermatology, addressing conditions like acne, hyperpigmentation, and eczema, affecting millions of Americans. The platform aims to provide high-efficacy treatments accessible online, eliminating the need for traditional doctor visits. Developed with board-certified dermatologists, METHODIQ integrates AI-powered skin analysis and progress tracking to offer personalized care. This launch represents a significant expansion for ODDITY, leveraging its technology and direct-to-consumer model to enter the medical care market, promising long-term growth potential.
The most recent analyst rating on (ODD) stock is a Buy with a $44.00 price target. To see the full list of analyst forecasts on ODDITY Tech Ltd. Class A stock, see the ODD Stock Forecast page.
On November 13, 2025, ODDITY Tech Ltd. held its Annual General Meeting of Shareholders in Tel Aviv-Jaffa, Israel. During the meeting, shareholders approved all proposals in accordance with Israeli Companies Law and the company’s amended articles of association, which were outlined in the proxy statement submitted to the SEC on September 30, 2025.
The most recent analyst rating on (ODD) stock is a Buy with a $44.00 price target. To see the full list of analyst forecasts on ODDITY Tech Ltd. Class A stock, see the ODD Stock Forecast page.